ABUS – arbutus biopharma corporation (US:NASDAQ)
Stock Stats
News
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels [Financial Post (Toronto, Ontario, Canada)]
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels [Yahoo! Finance]
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B [Yahoo! Finance]
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Form SC 13G Arbutus Biopharma Corp Filed by: MORGAN STANLEY
Form 8-K Arbutus Biopharma Corp For: Jun 06
Form 8-K Arbutus Biopharma Corp For: Jun 05
Form 8-K Arbutus Biopharma Corp For: May 22
Form 4 Arbutus Biopharma Corp For: May 23 Filed by: BURGESS DANIEL D
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.